Accessibility Menu
Knight Therapeutics logo

Knight Therapeutics(TSX) GUD

Market CapCA$948.92MMarket cap calculated using publicly traded shares outstanding only. Does not include unlisted, private, or dual-class non-traded shares. Implied market cap may vary.
Since IPO (2014)+152%
5 Year+79%
1 Year+50%
1 Month-1%
CA$9.66
+0.00%
+0.00Today
Knight Therapeutics last closing stock price
MetricPriceDate
Last closeCAD 9.662026-08-24
Knight Therapeutics stock price return by period
PeriodPrice returnPrice at period startPeriod start date
1 week-1.23%CAD 9.782026-08-17
1 month-0.72%CAD 9.732026-07-24
3 month+18.38%CAD 8.162026-05-26
Year to date+59.67%CAD 6.052025-12-31
1 year+49.77%CAD 6.452025-08-22
3 year+110.92%CAD 4.582023-08-25
5 year+78.56%CAD 5.412021-08-25
Since inception+152.22%CAD 3.832014-03-03

Knight Therapeutics Financials at a Glance

Market Cap

CA$948.92MMarket cap calculated using publicly traded shares outstanding only. Does not include unlisted, private, or dual-class non-traded shares. Implied market cap may vary.

Revenue (TTM)

CA$547.31M

Net Income (TTM)

CA$14.87M

EPS (TTM)

CA$0.15

P/E Ratio

64.10

Dividend

CA$0.00

Beta (Volatility)

0.40 (Low)

Price

CA$9.66

Volume

91,321

Open

CA$9.66

Previous Close

CA$9.66

Daily Range

CA$9.38 - CA$9.83

52-Week Range

CA$5.66 - CA$10.17

Estimated Earnings Date

Nov 5, 2026

GUD News

No articles available.

Motley Fool Moneyball Superscore

Our CEO Is Handing Members His Secret Weapon

It's called Motley Fool Moneyball, our new proprietary AI tool

We spent over half a million dollars in R&D to build a tool that makes stock research faster, sharper, and smarter. Our analysts use it every day, and now, you can too.

Get Access Now

About Knight Therapeutics

Knight Therapeutics Inc. is a Montreal-based specialty pharmaceutical company that focuses on the development, acquisition, and distribution of a diverse range of pharmaceutical products and medical devices. Established in 2013, the company operates primarily in Canada and Latin America, offering innovative treatments for various medical conditions.

Products and Services
  • Offers treatments for cancer, including Nerlynx and Tafasitamab
  • Provides medications for infectious diseases, such as Ambisome and Cresemba
  • Includes consumer health products like Exelon for dementia management
Growth Outlook
  • Strong presence in Latin America supports market expansion opportunities
  • Continued investment in R&D aims to enhance product pipeline
  • Strategic partnerships may drive future revenue growth
Financial Highlights
  • Q2 2026 revenue of CAD 144.2 million, showing resilience
  • Trailing twelve months (TTM) gross profit margin at 36.9%
  • Cash and short-term investments totaled CAD 109.6 million as of Q2 2026
Knight Therapeutics Inc. has established itself as a key player in the specialty pharmaceutical sector, with a robust portfolio of products addressing critical health needs. The company's focus on innovation and strategic growth initiatives positions it well for future success. Recent financial performance indicates a solid revenue base, with a notable gross profit margin that reflects operational efficiency. The strong cash position provides a buffer for ongoing investments in research and development, which is crucial for maintaining a competitive edge in the pharmaceutical industry. Overall, Knight Therapeutics Inc. presents a compelling opportunity for investors interested in the healthcare sector.
AI Generated • Aug 24, 2026

Industry

Pharmaceuticals

Sector

Health Care

Employees

830

CEO

Samira Sakhia, MBA

Website

www.gud-knight.com

Headquarters

Montreal, QC H4M 2P2, CA

GUD Financials

Key Financial Metrics (TTM)

Gross Margin

36.88%

Operating Margin

4.82%

Net Income Margin

2.72%

Return on Equity

1.91%

Return on Capital

-0.26%

Return on Assets

1.42%

Earnings Yield

1.56%

Dividend Yield

0.00%

Payout Ratio

0.00%

Stock Overview

Market Cap

CA$948.92MMarket cap calculated using publicly traded shares outstanding only. Does not include unlisted, private, or dual-class non-traded shares. Implied market cap may vary.

Shares Outstanding

98.23M

Volume

91.32K

Avg. Volume

99.00K

Financials (TTM)

Gross Profit

CA$201.84M

Operating Income

CA$26.39M

EBITDA

CA$90.25M

Operating Cash Flow

CA$112.90M

Capital Expenditure

-CA$4.86M

Free Cash Flow

CA$108.04M

Cash & ST Invst.

CA$109.60M

Total Debt

CA$34.28M

Knight Therapeutics Performance Analysis

Knight Therapeutics annual revenue and year-over-year revenue growth by fiscal year
Fiscal yearPeriod endRevenueYoY growth
20222022-12-31CAD 293,563,00020.6%
20232023-12-31CAD 328,199,00011.8%
20242024-12-31CAD 371,304,00013.1%
20252025-12-31CAD 450,088,00021.2%
Knight Therapeutics sequential (quarter-over-quarter) revenue growth by fiscal quarter
Fiscal quarterPeriod endQoQ growth
Q32025-09-3013.2%
Q42025-12-319.5%
Q12026-03-3111.5%
Q22026-06-30-2.8%
Knight Therapeutics annual diluted earnings per share and year-over-year EPS growth by fiscal year
Fiscal yearPeriod endDiluted EPSYoY growth
20222022-12-31CAD -0.26N/A
20232023-12-31CAD -0.16-39.8%
20242024-12-31CAD 0.04N/A
20252025-12-31CAD -0.05N/A
Knight Therapeutics sequential (quarter-over-quarter) diluted earnings per share growth by fiscal quarter
Fiscal quarterPeriod endQoQ growth
Q32025-09-3070.8%
Q42025-12-31335.0%
Q12026-03-3145.6%
Q22026-06-30-126.3%

Revenue Growth Rate

Annual and quarterly growth comparison

Earnings Per Share Growth Rate

Annual and quarterly EPS growth comparison

Quarterly Performance

Name
Q2 2026YOY CHG

Revenue

CA$144.21M

+34.3%

Gross Profit

CA$56.16M

+25.3%

Gross Margin

38.94%

N/A

Market Cap

CA$948.92MMarket cap calculated using publicly traded shares outstanding only. Does not include unlisted, private, or dual-class non-traded shares. Implied market cap may vary.

N/A

Market Cap/Employee

CA$1.14M

N/A

Employees

830

N/A

Net Income

-CA$3.36M

+73.4%

EBITDA

CA$23.97M

+2282.8%

Quarterly Fundamentals

Name
Q2 2026YOY CHG

Total Cash

CA$109.60M

-5.9%

Total Debt

CA$34.28M

-67.3%

Accounts Receivable

CA$144.85M

+34.5%

Inventory

CA$144.57M

-2.7%

Long Term Debt

CA$14.56M

-82.4%

Short Term Debt

CA$19.72M

-11.2%

Return on Assets

1.42%

N/A

Return on Invested Capital

3.06%

N/A

Free Cash Flow

CA$26.97M

+653.1%

Operating Cash Flow

CA$27.59M

+36.2%

Other Investments to Explore

People Also Watch

Symbol / CompanyPricePrice Chg
KSI.TOKneat.com, Inc.
CA$6.50+0.00%
VHI.TOVitalhub Corp.
CA$7.89-2.23%
CPH.TOCipher Pharmaceuticals Inc.
CA$14.10+0.00%
ACB.TOAurora Cannabis Inc.
CA$5.47+1.11%

Trending Stocks

Symbol / CompanyPricePrice Chg
SOXLDirexion Shares ETF Trust - Direxion Daily Semiconductor Bull 3x ETF
$111.16-0.08%
IBITiShares Bitcoin Trust
$44.64+0.02%
SOXSDirexion Shares ETF Trust - Direxion Daily Semiconductor Bear 3x ETF
$50.75+0.08%
TQQQProShares Trust - ProShares UltraPro Qqq
$69.01-0.03%

Questions About GUD

What is the current price of Knight Therapeutics?

Knight Therapeutics is trading at CA$9.66 per share.

What is the 52-week range for Knight Therapeutics?

Over the past 52 weeks, Knight Therapeutics has traded between CA$5.66 and CA$10.17.

How much debt does Knight Therapeutics have?

As of the most recent reporting period, Knight Therapeutics reported total debt of CA$34.28M.

How much cash does Knight Therapeutics have on hand?

Knight Therapeutics reported CA$93.54M in cash and cash equivalents in its most recent financial results.

What is Knight Therapeutics’s dividend yield?

Knight Therapeutics does not currently have a dividend yield.

Premium Investing Services

Invest better with The Motley Fool. Get stock recommendations, portfolio guidance, and more from The Motley Fool's premium services.

View Premium Services